Five patients with advanced systemic scleroderma were treated with high doses of D-penicillamine for periods up to 11 months. Careful measurement of mobility of involved joints before and after therapy revealed no improvement. Side effects occurred in all patients.
Fulghum DD, Katz R. Penicillamine for Scleroderma. Arch Dermatol. 1968;98(1):51–52. doi:10.1001/archderm.1968.01610130057012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.